Home | Coverage | Agents | Pulse | LogIn |
| Darwin Score | -10 |
| Ticker | MSB |
| Latest Price | 1.63 AUD as of close on 04-Jul-2025 |
| 3 Month price range | 1.57 to 1.88 AUD |
| Market Capitalisation | 2.07Bn AUD |
| Country | Australia |
| Region | Asia |
| Economic Sector | Health Care |
| Business Sector | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Sub-Industry | Biotechnology |
| Description | Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia. See More ... |
| Company URL | https://www.mesoblast.com |
| See Darwins Full Analysis for Mesoblast Ltd |
Tell Me About (TMA) is Darwins structured scoring system for assets. Here are the scores from the key TMA sections for Mesoblast Ltd. Further information and full detail is available when you login.
| TMA Part | Focus of Analysis | TMA Score |
|---|---|---|
| Price | Analysis of performance, trend, RSI, OBV and moving averages | -16 |
| Sentiment | News and Candle Patterns. | 0 |
| Fundamentals | Analyst Ratings, Valuation and Dividend analysis. | -1 |
| Flow | Institutional, Fund and Insider buying and selling. | 0 |
| Models | Forecast models. | +7 |
There are 5 live alerts for Mesoblast Ltd.
There are 12 peers of Mesoblast Ltd.
| Asset Name | Industry Group | Perf(20d)% | Asset Score |
|---|---|---|---|
| Argenica Therapeutics Ltd (AGN) | Biotechnology | -2.0 | +22 |
| Arovella Therapeutics Ltd (ALA) | Biotechnology | +19.2 | +2 |
| CSL Ltd (CSL) | Biotechnology | -2.1 | +19 |
| Clinuvel Pharmaceuticals Ltd (CUV) | Biotechnology | -1.9 | +7 |
| Imugene Ltd (IMU) | Biotechnology | -23.7 | -9 |
| Opthea Ltd (OPT) | Biotechnology | 0 | -12 |
| PYC Therapeutics Ltd (PYC) | Biotechnology | +9.1 | +24 |
| Paradigm Biopharmaceuticals Ltd (PAR) | Biotechnology | +49.2 | +18 |
| Polynovo Ltd (PNV) | Biotechnology | -9.1 | +2 |
| Race Oncology Ltd (RAC) | Biotechnology | -0.4 | -9 |
| Telix Pharmaceuticals Ltd (TLX) | Biotechnology | -11.9 | +7 |
| Tissue Repair Ltd (TRP) | Biotechnology | +16.2 | -10 |
To see complete information on Mesoblast Ltd or any other assets please login.
If you do not already have an account you can register for a free trial of our service. This will let you explore all the analytical information we have on price, fundamantals, flow, sentiments & models for all the stocks under coverage. You will then be able to compare asset scores and perform a wide range of multi asset analysis such as Market Cycles and Relative Scores.
Follow Us | |
©2025 Darwin Knows - All Rights Reserved | |